Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous HSP-70 protein-peptide complex (AG-858) + imatinib
- Development stage
- Unknown
- Lead developer
- Agenus
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Oral
01
Overview
This combination therapy pairs AG-858, a personalized cancer vaccine based on heat shock protein 70 (HSP-70) protein-peptide complex derived from a patient's own tumor cells, with imatinib (Gleevec/Glivec), a BCR-ABL tyrosine kinase inhibitor. The combination aims to enhance treatment efficacy in chronic myelogenous leukemia (CML) by targeting multiple pathways simultaneously. While imatinib inhibits the BCR-ABL tyrosine kinase that drives CML progression, AG-858 is designed to stimulate an immune response against residual leukemia cells. This approach was investigated as a potential strategy to improve outcomes for patients who remained cytogenetically positive after imatinib treatment alone.
- Brand names
- AG-858 + Gleevec
- Other names
- AG-858 + Glivec
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFR (PDGFR family)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)
Beyond the preview
Go deeper on autologous HSP-70 protein-peptide complex (AG-858) + imatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous HSP-70 protein-peptide complex (AG-858) + imatinib.